Susquehanna Fundamental Investments LLC Purchases New Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Susquehanna Fundamental Investments LLC bought a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 18,020 shares of the company's stock, valued at approximately $5,987,000. Susquehanna Fundamental Investments LLC owned 0.06% of Medpace at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in MEDP. Hancock Whitney Corp grew its holdings in shares of Medpace by 1.0% in the fourth quarter. Hancock Whitney Corp now owns 48,304 shares of the company's stock worth $16,048,000 after acquiring an additional 484 shares during the period. MGO One Seven LLC grew its stake in shares of Medpace by 25.8% during the 4th quarter. MGO One Seven LLC now owns 989 shares of the company's stock valued at $329,000 after purchasing an additional 203 shares during the period. Dark Forest Capital Management LP purchased a new stake in shares of Medpace during the 4th quarter valued at about $626,000. Eversept Partners LP purchased a new stake in shares of Medpace during the 4th quarter valued at about $6,329,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Medpace by 104.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,571 shares of the company's stock worth $854,000 after purchasing an additional 1,314 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MEDP. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research report on Monday, March 24th. TD Cowen cut Medpace from a "buy" rating to a "hold" rating and decreased their target price for the stock from $370.00 to $328.00 in a report on Monday, April 14th. Truist Financial cut their price target on Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a report on Wednesday, April 23rd. Mizuho decreased their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Finally, Leerink Partners began coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective on the stock. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Medpace has an average rating of "Hold" and an average price target of $349.30.

Medpace Stock Up 0.9 %

NASDAQ MEDP traded up $2.86 during trading hours on Friday, reaching $305.11. The company's stock had a trading volume of 313,502 shares, compared to its average volume of 343,385. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The company has a market capitalization of $8.77 billion, a price-to-earnings ratio of 24.16, a PEG ratio of 3.81 and a beta of 1.55. The firm's 50-day moving average price is $309.90 and its 200-day moving average price is $330.13.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to analyst estimates of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter in the prior year, the business earned $3.20 earnings per share. Equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the transaction, the director now directly owns 2,998 shares in the company, valued at approximately $904,856.36. This represents a 36.35 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.30% of the company's stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.